Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade, metastasising
neoplasm of women, characterised by infiltration of the lung parenchyma with abnormal …
neoplasm of women, characterised by infiltration of the lung parenchyma with abnormal …
Renal disease in tuberous sclerosis complex: pathogenesis and therapy
HC Lam, BJ Siroky, EP Henske - Nature Reviews Nephrology, 2018 - nature.com
Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized by
hamartomatous tumours of the brain, heart, skin, lung and kidney. Patients with TSC show a …
hamartomatous tumours of the brain, heart, skin, lung and kidney. Patients with TSC show a …
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
Identifying the mechanisms underlying the regulation of immune checkpoint molecules and
the therapeutic impact of targeting them in cancer is critical. Here we show that high …
the therapeutic impact of targeting them in cancer is critical. Here we show that high …
Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
Abstract mTORC1 is hyperactive in multiple cancer types,. Here, we performed integrative
analysis of single cell transcriptomic profiling, paired T cell receptor (TCR) sequencing, and …
analysis of single cell transcriptomic profiling, paired T cell receptor (TCR) sequencing, and …
Lymphangioleiomyomatosis
SR Johnson - Orphan lung diseases: a clinical guide to rare lung …, 2023 - Springer
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease which predominantly
affects women. The disease occurs both sporadically and is common in women with …
affects women. The disease occurs both sporadically and is common in women with …
Pulmonary manifestations in tuberous sclerosis complex
Tuberous sclerosis complex has manifestations in many organ systems, including brain,
heart, kidney, skin, and lung. The primary manifestations in the lung are …
heart, kidney, skin, and lung. The primary manifestations in the lung are …
CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
B Zhang, J Liu, Y Mo, K Zhang, B Huang… - Frontiers in …, 2024 - frontiersin.org
A steady dysfunctional state caused by chronic antigen stimulation in the tumor
microenvironment (TME) is known as CD8+ T cell exhaustion. Exhausted-like CD8+ T cells …
microenvironment (TME) is known as CD8+ T cell exhaustion. Exhausted-like CD8+ T cells …
Mast-cell tryptase release contributes to disease progression in lymphangioleiomyomatosis
R Babaei-Jadidi, A Dongre, S Miller… - American Journal of …, 2021 - atsjournals.org
Rationale: Lymphangioleiomyomatosis (LAM) is a multisystem disease that causes lung
cysts and respiratory failure. Loss of TSC (tuberous sclerosis complex) gene function results …
cysts and respiratory failure. Loss of TSC (tuberous sclerosis complex) gene function results …
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like …
YM Zhong, K Yin, Y Chen, Z Xie, ZY Lv… - Frontiers in …, 2022 - frontiersin.org
Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein–Barr virus
(EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint …
(EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint …
[HTML][HTML] IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
AJ Valvezan, MC McNamara, SK Miller, ME Torrence… - JCI insight, 2020 - ncbi.nlm.nih.gov
Recent studies in distinct preclinical tumor models have established the nucleotide
synthesis enzyme inosine-5′-monophosphate dehydrogenase (IMPDH) as a viable target …
synthesis enzyme inosine-5′-monophosphate dehydrogenase (IMPDH) as a viable target …